Literature DB >> 17985928

Characterization of nonenzymatic glycation on a monoclonal antibody.

Lowell J Brady1, Theresa Martinez, Alain Balland.   

Abstract

We present here an improved analytical method for the analysis of glycation events in proteins. Nonenzymatic glycation of an IgG2 monoclonal antibody was studied using affinity chromatography, mass spectrometry, and chemical derivatization. Analysis of both forced-degraded and bulk-drug substance (BDS) samples showed the presence of glycated protein. A new peptide mapping procedure, incorporating derivatization using sodium borohydride, allowed the development of a sensitive method for detecting and identifying the sites of modification. When combined with tandem mass spectrometry, peptides glycated by glucose showed dramatically improved MS/MS spectra as compared to underivatized controls. Using these methods we were able to map a number of glycation sites in both forced-degraded and BDS samples that were distributed across both light and heavy chain subdomains. The combination of affinity chromatography, high-resolution mass spectrometry, and a simple derivatization procedure should allow the facile analysis of glycation for other antibody and protein samples.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985928     DOI: 10.1021/ac7017469

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  22 in total

1.  Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis.

Authors:  Xiaotao Duan; Lipeng Dai; Shang-Chiung Chen; Joseph P Balthasar; Jun Qu
Journal:  J Chromatogr A       Date:  2012-06-21       Impact factor: 4.759

2.  Molecular mass analysis of antibodies by on-line SEC-MS.

Authors:  Lowell J Brady; John Valliere-Douglass; Theresa Martinez; Alain Balland
Journal:  J Am Soc Mass Spectrom       Date:  2008-01-04       Impact factor: 3.109

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

4.  A chemical and computational approach to comprehensive glycation characterization on antibodies.

Authors:  Ramsey A Saleem; Brittany R Affholter; Sihong Deng; Phil C Campbell; Kelli Matthies; Catherine M Eakin; Alison Wallace
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 5.  Glycation of antibodies: Modification, methods and potential effects on biological functions.

Authors:  Bingchuan Wei; Kelsey Berning; Cynthia Quan; Yonghua Taylor Zhang
Journal:  MAbs       Date:  2017-03-08       Impact factor: 5.857

6.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

7.  Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells.

Authors:  Christopher S Spahr; Mark E Daris; Kevin C Graham; Brian D Soriano; Jennitte L Stevens; Stone D-H Shi
Journal:  MAbs       Date:  2018-09-20       Impact factor: 5.857

8.  Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry.

Authors:  Sara Rosati; Yang Yang; Arjan Barendregt; Albert J R Heck
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

Review 9.  Photo-Degradation of Therapeutic Proteins: Mechanistic Aspects.

Authors:  Christian Schöneich
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

Review 10.  A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease.

Authors:  Qibin Zhang; Jennifer M Ames; Richard D Smith; John W Baynes; Thomas O Metz
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.